AZD1656 News - LARVOL Sigma

||||||||||  AZD1656 / AstraZeneca
Trial completion date:  ADOPTION: AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (clinicaltrials.gov) -  May 17, 2023
P2, N=50, Active, not recruiting,  Sponsor: Queen Mary University of London
Trial completion date: May 2023 --> Aug 2023

||||||||||  AZD1656 / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date:  ADOPTION: AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (clinicaltrials.gov) -  Nov 21, 2022
P2, N=50, Active, not recruiting,  Sponsor: Queen Mary University of London
Trial completion date: May 2023 --> Aug 2023 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2022 --> Mar 2023

|||||||||| AZD1656 / AstraZeneca
Preclinical, Journal: Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats. (Pubmed Central) - Nov 2, 2022
In conclusion, intermittent AZD1656 treatment timed to feeding periods promotes glucose disposal when needed the most, restores metabolic flexibility and hepatic insulin sensitivity, and thereby avoids hepatic steatosis. Thus, chronotherapeutic approaches may benefit the development of GKAs and other drugs acting on metabolic targets.

|||||||||| AZD1656 / AstraZeneca
ADOPTION Study Protocol: AZD1656 in Transplantation With Diabetes to Promote Immune Tolerance () - Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_4472;
We hope to demonstrate that AZD1656 increases Treg localisation to the renal transplant and provides an effective and safe adjunct for the management of diabetes in the early post-transplant period. A positive signal generated by this pilot study would provide future opportunities for further study and we look forward to sharing our results with the ASN in the near future.

|||||||||| AZD1656 / AstraZeneca
Clinical, Journal: A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial - implications for therapeutic immune modulation. (Pubmed Central) - Aug 24, 2022
P2
Phase 2 trials of this size carry the risk of false positive results and confirmation of these results in a larger clinical trial is now required. UK Research and Innovation (UKRI) 'Innovate UK' programme and Excalibur Medicines Ltd.

|||||||||| AZD1656 / AstraZeneca
Development of the glucokinase activator AZD1656: Part 2 (W176a (McCormick Place Convention Center)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_7025;
Downstream challenges included an amidation reaction with a pyrazine coupling partner made using a Curtius rearrangement performed in batch mode, and the development of crystallization conditions that allowed the reproducible isolation of a slow-growing polymorph of the API. The processes developed were tested as part of a 500kg manufacture of AZD1656.

|||||||||| AZD1656 / AstraZeneca
Chronotherapy with the Glucokinase Activator AZD1656 Greatly Affects Its Ability to Improve Metabolism in Obese Zucker Rats (245 (Level 2); Board No. 193) - May 11, 2022 - Abstract #ADA2022ADA_2199;
In conclusion, intermittent AZD1656 dosing timed to feeding periods promotes glucose disposal when needed the most, while the daily drug holiday allows for maintained metabolic flexibility and avoids hepatic steatosis. Chronotherapeutic approaches should be considered for the development of GKAs and other drugs acting on metabolic targets.

|||||||||| AZD1656 / AstraZeneca, dorzagliatin (HMS5552) / Hua Medicine
Journal: Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. (Pubmed Central) - Mar 23, 2022
Among these agents, dorzagliatin is currently being investigated in phase III clinical trials, while PB-201 and AZD-1656 have reached phase II clinical trials. This article describes the mechanism of action of GK in diabetes and of action of GKA at the protein level, and provides a review of the research, trends, and prospects regarding the use of GKA in this setting.

||||||||||  AZD1656 / AstraZeneca
New P2 trial:  ADOPTION: AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (clinicaltrials.gov) -  Jan 30, 2022
P2, N=50, Recruiting,  Sponsor: Queen Mary University of London

|||||||||| PF-04991532 / Pfizer, AZD1656 / AstraZeneca
Journal: Chronic Glucokinase Activator treatment activates liver Carbohydrate Response Element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. (Pubmed Central) - Jun 26, 2021
Chronic GKA treatment of C57BL/6 mice for 8 weeks activates liver ChREBP and improves the resilience of hepatocytes to compromised ATP homeostasis during high-substrate challenge. These changes are associated with raised mRNA levels of ChREBP-β and both catalytic subunits of AMP-activated protein kinase.

||||||||||  AZD1656 / AstraZeneca
Trial completion:  ARCADIA: AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (clinicaltrials.gov) -  May 13, 2021
P2, N=156, Completed,  Sponsor: St George Street Capital
These changes are associated with raised mRNA levels of ChREBP-β and both catalytic subunits of AMP-activated protein kinase. Active, not recruiting --> Completed

||||||||||  AZD1656 / AstraZeneca
Enrollment closed:  ARCADIA: AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (clinicaltrials.gov) -  Apr 20, 2021
P2, N=156, Active, not recruiting,  Sponsor: St George Street Capital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  AZD1656 / AstraZeneca
Trial completion date, Trial primary completion date:  ARCADIA: AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (clinicaltrials.gov) -  Nov 9, 2020
P2, N=150, Recruiting,  Sponsor: St George Street Capital
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021

||||||||||  AZD1656 / AstraZeneca
Enrollment open:  ARCADIA: AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (clinicaltrials.gov) -  Sep 27, 2020
P2, N=150, Recruiting,  Sponsor: St George Street Capital
Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021 Not yet recruiting --> Recruiting

||||||||||  AZD1656 / AstraZeneca
New P2 trial:  ARCADIA: AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (clinicaltrials.gov) -  Aug 17, 2020
P2, N=150, Not yet recruiting,  Sponsor: St George Street Capital

||||||||||  AZD1656 / AstraZeneca
Enrollment change:  Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin (clinicaltrials.gov) -  Oct 15, 2012
P2a, N=27, Completed,  Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=20 --> 27



	Diseases Companies Products Productz Mechanisms of Action Sites